Edesa Biotech Inc 2025年度季度报告

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes☐No☒ As of May 14, 2025, the registrant had7,022,678common shares issued and outstanding. Table of Contents PART 1–FINANCIAL INFORMATION Edesa Biotech, Inc.Condensed Interim Consolidated Balance Sheets 1. Nature of Operations Edesa Biotech, Inc. (the “Company” or “Edesa”) is a biopharmaceutical company focused on acquiring, developing andcommercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. TheCompany is organized under the laws of British Columbia, Canada and is headquartered in Markham, Ontario. It operates under its The Company’s common shares trade on The Nasdaq Capital Market in the United States under the symbol “EDSA”. Going Concern These unaudited condensed consolidated financial statements have been prepared on a going concern basis which presumes therealization of assets and the discharge of liabilities in the normal course of operations for at least the next twelve months. For the six months ended March 31, 2025, the Company incurred a comprehensive loss of $3.3million resulting in an accumulateddeficit of $61.9million. For the six months ended March 31, 2025, the Company had a net cash outflow from operating activitiesof $3.9million and ended the period with $13.9million in cash and cash equivalents and a working capital of $13.5million.During the six month period ended March 31, 2025, the Company received gross proceeds of $15.0million from the sale ofpreferred shares and common shares in a private placement and $1.5million from the sale of preferred shares to an entity These unaudited condensed consolidated financial statements do not give effect to any adjustments which would be necessaryshould the Company be unable to continue as a going concern and, therefore, be required to realize its assets and discharge itsliabilities in other than the normal course of business and at amounts different from those reflected in the accompanying 2. Basis of Presentation The accompanying unaudited condensed interim consolidated financial statements have been prepared in accordance withaccounting principles generally accepted in the United States (U.S. GAAP) for interim financial information and with theinstructions to Form 10-Q. They do not include all information and footnotes necessary for a fair presentation of financial position,results of operations and cash flows in conformity with U.S. GAAP for complete financial statements. These unaudited condensed The accompanying unaudited condensed interim consolidated financial statements include the accounts of the Company and itswholly owned subsidiaries. All intercompany balances and transactions have been eliminated on consolidation. All adjustments(consisting of normal recurring adjustments and accruals) considered necessary for a fair presentation of the results of operations Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates andassumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date ofthe financial statements and the reported amounts of revenue and expenses during the period or year. Actual results could differfrom those estimates. Areas where significant judgment is involved in making estimates are valuation of accounts and other Functional and reporting currencies The consolidated financial statements of the Company are presented in U.S. dollars, unless otherwise stated, which is theCompany’s and its wholly owned subsidiary’s, Edesa Biotech USA, Inc., functional currency. The functional currency of the 3. Intangible Assets Acquired license In April 2020, the Company entered into a license agreement with a pharmaceutical development company to obtain exclusiveworld-wide rights to know-how, patents and data relating to certain monoclonal antibodies (the Constructs), including sublicensingrights. Unless earlier terminated, the term of the license agreement will remain in effect for25years from the date of first Under the license agreement, the Compan